Clinical Report: Perspectives on Swallowing and Communication Challenges Following NPC
Overview
This qualitative study explores the swallowing and communication challenges faced by Malaysian males with nasopharyngeal cancer (NPC). Findings indicate a significant impact on quality of life due to these difficulties, highlighting the need for targeted interventions.
Background
Nasopharyngeal cancer (NPC) is a prevalent malignancy in Malaysian males, particularly among Chinese Malaysians. Treatment often results in complications such as dysphagia and speech difficulties, which can severely affect patients' quality of life. Understanding these challenges is crucial for developing effective, culturally sensitive care strategies.
Data Highlights
No numerical data presented in the article.
Key Findings
NPC is the fifth most common cancer in Malaysian men, with higher incidence in Chinese Malaysians.
Common treatment-related symptoms include xerostomia, dysphagia, and speech difficulties.
Patients often report a lack of understanding regarding swallowing issues, necessitating proactive support from healthcare professionals.
Impaired communication significantly affects the quality of life in NPC patients.
Existing studies in Malaysia have primarily focused on dysphagia, neglecting the communication aspect.
Clinical Implications
Healthcare providers should be aware of the dual challenges of swallowing and communication faced by NPC patients. Implementing comprehensive assessments and interventions can improve patient outcomes and quality of life. Culturally sensitive approaches are essential in addressing the unique needs of Malaysian patients.
Conclusion
Addressing the swallowing and communication challenges in NPC patients is vital for enhancing their quality of life. Further research and tailored interventions are needed to support this patient population effectively.
An NCI/NIH funded Phase 1/2 clinical study (NCT03727061) will evaluate the safety and efficacy of adjuvant Photofrin® mediated I-PDT in patients with locally advanced or recurrent HNC who failed to respond to standard therapy and are not amenable to standard curative treatment.